Build an Efficient, High Quality Incidental Findings Program
Empower your team to build an efficient, high quality incidental findings program
Reimagine multidisciplinary conference organization and patient presentation
Lung Cancer Screening
Transform your lung cancer screening program
Provide data-driven therapy response assessments
Integrated workflow solution for early identification of incidental findings, comprehensive patient tracking, and radiomic-informed decisions.
HealthMyne’s Incidental Findings Module is designed to simplify the process of identifying and ensuring follow-up for incidental findings discovered in CT, MRI, and PET imaging studies. Radiologists mark incidentals within their standard workflows and radiomic decision support guides them to the correct recommendations.
Research shows that as little as *35% of incidental findings receive appropriate follow up. Earlier detection is a key factor in survival for most cancers and failure to follow-up can expose radiologists, oncologists and the entire multidisciplinary care team to future liability.
Implement a reliable program for flagging and monitoring incidental findings
- Provide a higher standard of quality care
- Provide access to more patients
- Expedite patient care
- Improve patient outcomes and experience
- Foster multidisciplinary collaboration and communication
- Incorporate radiomic data for more informed treatment
Instantly consult follow-up guidelines based on leading research
The system guides users through a decision tree using quantitative data extracted from Radiomic Precision Metrics (RPM) combined with data from the EMR.
- Lung: Fleischner Society Guidelines
- Liver: ACR Guidelines
- Pancreas: ACR Guidelines
- Kidney: ACR Guidelines
- Adrenal Gland: ACR Guidelines
HealthMyne incidental findings helps ensure timely and appropriate care
As little as 35% of incidental findings reported in radiology reports may not receive proper follow-up.1
In one study of incidental pulmonary nodules detected on CT pulmonary angiography, the authors found that approximately 10% of studies showed nodules requiring follow-up; however 71% were not.2